Article citationsMore >>

Nguyen MC, Shah MH, Liebner DA, et al. The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series. Journal of the National Comprehensive Cancer Network, 2018; 16(11), 1279-1283.

has been cited by the following article:

Article

Complete Disappearance of Numerous Hepatic and Adrenal Metastases after One Dose of Pembrolizumab in a Patient with Metastatic Malignant Melanoma

1Hospital Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Dr. Lebanon, NH, 03756

2Hematology-Oncology, Norris Cotton Cancer Center, One Medical Center Dr. Lebanon, NH, 03756


American Journal of Medical Case Reports. 2019, Vol. 7 No. 2, 22-23
DOI: 10.12691/ajmcr-7-2-2
Copyright © 2019 Science and Education Publishing

Cite this paper:
Muhammad Zubair Afzal, Keisuke Shirai. Complete Disappearance of Numerous Hepatic and Adrenal Metastases after One Dose of Pembrolizumab in a Patient with Metastatic Malignant Melanoma. American Journal of Medical Case Reports. 2019; 7(2):22-23. doi: 10.12691/ajmcr-7-2-2.

Correspondence to: Muhammad  Zubair Afzal, Hospital Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Dr. Lebanon, NH, 03756. Email: Muhammad.afzal@hitchcock.org

Abstract

Although pembrolizumab is the mainstay treatment in metastatic malignant melanoma and have shown a durable response. Heterogeneous or no response has been observed in 30-40% of the cases of metastatic malignant melanoma. Metastatic lung lesions are sensitive to checkpoint inhibitor therapy whereas liver and adrenal metastases show a variable response. We are reporting a case of malignant melanoma with numerous liver and adrenal metastases showing a significant and durable response to just a single dose of pembrolizumab.

Keywords